Please enable Javascript
ASCO 2023
American Society of Clinical Oncology 2023 Annual Meeting
Advertisement
Real-world Association of Tumor-Informed MRD With Clinical Outcomes for MIBC
Ajitha Kommalapati, MD
ASCO 2023
|
March 11, 2024
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
View More
Drs. Gupta, Koshkin on EV-103 Cohort K Results and Toxicities
Shilpa Gupta, MD
ASCO 2023
|
August 4, 2023
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
View More
Drs. Gupta, Koshkin on EV-103 Design and Long-term Cohort A Results for Patients With aUC
Shilpa Gupta, MD
ASCO 2023
|
August 31, 2023
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
View More
Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE Study
Tanya Jindal
ASCO 2023
|
July 28, 2023
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
View More
Dr. Thomas Hutson on Long-Term Durable Response After 4 Years Follow-Up in the CLEAR Study
Thomas Hutson, DO, PharmD, FACP
ASCO 2023
|
July 17, 2023
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
View More
Dr. Thomas Hutson on Conventional and Novel Combination Therapies for First-Line Advanced RCC
Thomas Hutson, DO, PharmD, FACP
ASCO 2023
|
July 17, 2023
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
View More
Drs. Bossi, Wallis on the Right Patients for Radiotherapy When Presenting With De Novo mCSPC
Alberto Bossi, MD
ASCO 2023
|
August 23, 2023
Drs. Bossi and Wallis conclude with a breakdown of the right patients for radiotherapy when presenting with de novo mCSPC.
View More
Drs. Bossi, Wallis on the Synergistic Effects of Abiraterone, Radiotherapy for De Novo mCSPC
Alberto Bossi, MD
ASCO 2023
|
August 23, 2023
Drs. Bossi, Wallis address which patients with mCSPC experience synergistic effects from abiraterone plus radiotherapy.
View More
Drs. Bossi, Wallis on Prostate Irradiation in Men With De Novo, Low-Volume mCSPC
Alberto Bossi, MD
ASCO 2023
|
August 23, 2023
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as an LBA at the ASCO Annual Meeting.
View More
Dr. Laurence Albiges on Results of Arm B5 of KEYMAKER-U03B for Belzutifan Plus Lenvatinib in accRCC
Laurence Albiges, MD, PhD
ASCO 2023
|
August 1, 2023
Dr. Albiges details the KEYMAKER-U03B study, outcomes for patients in arm B5, and next lines of research for belzutifan.
View More
Drs. Loriot, Koshkin on Results From Cohort 1 of the THOR Study
Yohann Loriot, MD, PhD
ASCO 2023
|
August 1, 2023
Drs. Loriot, Koshkin summarize erdafitinib versus chemotherapy in patients with advanced UC with select FGFR alterations.
View More
Drs. Lee, McKay on KEYNOTE-B61 for Non-Clear Cell RCC
Chung-Han Lee, MD, PhD
ASCO 2023
|
August 23, 2023
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
View More
Dr. Miron on Kidney Cancer Updates, Molecular Alterations in Intraductal Carcinoma of the Prostate
Benjamin Miron, MD
ASCO 2023
|
June 16, 2023
Dr. Miron provides an overview of clinical implications of molecular alterations in intraductal carcinoma of the prostate.
View More
Drs. Powles, Koshkin on the Q-TWiST Analysis for JAVELIN Bladder 100
Thomas Powles, MBBS, MRCP, MD
ASCO 2023
|
June 15, 2023
Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.
View More
Drs. Lerner, Koshkin on SWOG S1011 Results for Lymphadenectomy for Metastatic Urothelial Carcinoma
Seth Lerner, MD, FACS
ASCO 2023
|
June 20, 2023
Drs. Lerner and Koshkin explain the implications of the latest data from the SWOG S1011 study for mUC.
View More
Drs. Friedlander, Koshkin on Long-Term Follow-Up of EV-103
Terence Friedlander, MD
ASCO 2023
|
June 15, 2023
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.
View More
Drs. Siefker-Radtke, Koshkin on the NORSE Study for Metastatic Urothelial Carcinoma
Arlene O. Siefker-Radtke, MD
ASCO 2023
|
June 15, 2023
Drs. Siefker-Radtke and Koshkin detail the NORSE study design, results, and implications for treating patients with mUC.
View More
Drs. Fizazi, Wallis on Updated Data from TALAPRO-2
Karim Fizazi, MD, PhD
ASCO 2023
|
August 1, 2023
Drs. Fizazi and Wallis detail the latest updates regarding TALAPRO-2 for patients with mCRPC and HRR gene alterations.
View More
Drs. Rini, Wallis on a 5-Year Analysis of KEYNOTE-426 for Advanced Clear Cell RCC
Brian Rini, MD, FASCO
ASCO 2023
|
June 5, 2023
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
View More
The Oncology Brothers, Dr. Wallis Give Their Thoughts on PROpel, TALAPRO-2, and EV-103 Cohort K
Oncology Brothers
ASCO 2023
|
June 6, 2023
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
View More
Load More
Advertisement
Advertisement
Advertisement